-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Rz8MMhW0k+xCF/MBirMoXzWgV7I06nGMYi8DFqM7JawGqFEro5Oh/D1dB+VjCxGZ jfuzrR9fBk07bgIaObuBZA== 0001264908-08-000003.txt : 20080808 0001264908-08-000003.hdr.sgml : 20080808 20080808162036 ACCESSION NUMBER: 0001264908-08-000003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080807 FILED AS OF DATE: 20080808 DATE AS OF CHANGE: 20080808 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC CENTRAL INDEX KEY: 0001003124 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561640186 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRANGE DAVID L CENTRAL INDEX KEY: 0001264908 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27570 FILM NUMBER: 081002789 BUSINESS ADDRESS: STREET 1: 3151 S 17TH ST CITY: WILMINGTON STATE: NC ZIP: 28412 BUSINESS PHONE: 9102510081 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2008-08-07 0001003124 PHARMACEUTICAL PRODUCT DEVELOPMENT INC PPDI 0001264908 GRANGE DAVID L 27W 631 SWAN LAKE DRIVE WHEATON IL 60187 1 0 0 0 Common Stock 2008-08-07 4 M 0 6126 33.82 A 14929 D Common Stock 2008-08-07 4 M 0 3973 35.38 A 18902 D Common Stock 2008-08-07 4 S 0 10099 41.35 D 8803 D Stock Options (to buy) 33.82 2008-08-07 4 M 0 6126 0 D 2007-05-16 2017-05-15 Common Stock 6126 0 D Stock Options (to buy) 35.38 2008-08-07 4 M 0 3973 0 D 2006-05-17 2016-05-16 Common Stock 3973 0 D Stock Options (to buy) 42.77 2008-05-21 2018-05-20 Common Stock 6265 6265 D $41.35 represents a weighted average price for the shares sold. The range of prices for the transactions was $41.35-$41.39. Upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available. Lisa C. Noecker attorney-in-fact for David L. Grange 2008-08-08 -----END PRIVACY-ENHANCED MESSAGE-----